254 related articles for article (PubMed ID: 31793344)
21. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
Stewart J; Fleshner N; Cole H; Toi A; Sweet J
J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
[TBL] [Abstract][Full Text] [Related]
23. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Zhou M; Jiang Z; Epstein JI
Am J Surg Pathol; 2003 Jun; 27(6):772-8. PubMed ID: 12766580
[TBL] [Abstract][Full Text] [Related]
24. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
25. Analysis of enzyme reactions using NMR techniques: A case study with α-methylacyl-CoA racemase (AMACR).
Woodman TJ; Lloyd MD
Methods Enzymol; 2023; 690():159-209. PubMed ID: 37858529
[TBL] [Abstract][Full Text] [Related]
26. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
27. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Jiang N; Zhu S; Chen J; Niu Y; Zhou L
PLoS One; 2013; 8(10):e74386. PubMed ID: 24130666
[TBL] [Abstract][Full Text] [Related]
28. Quadriplex model enhances urine-based detection of prostate cancer.
Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966
[TBL] [Abstract][Full Text] [Related]
29. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
30. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
31. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
32. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.
Shah RB; Tadros Y; Brummell B; Zhou M
Hum Pathol; 2013 May; 44(5):786-94. PubMed ID: 23158212
[TBL] [Abstract][Full Text] [Related]
34. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Farinola MA; Epstein JI
Hum Pathol; 2004 Oct; 35(10):1272-8. PubMed ID: 15492996
[TBL] [Abstract][Full Text] [Related]
35. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
[TBL] [Abstract][Full Text] [Related]
36. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
Zhou M; Aydin H; Kanane H; Epstein JI
Am J Surg Pathol; 2004 Feb; 28(2):239-43. PubMed ID: 15043314
[TBL] [Abstract][Full Text] [Related]
37. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Barry M; Dhillon PK; Stampfer MJ; Perner S; Ma J; Giovannucci E; Kurth T; Mucci LA; Rubin MA
Prostate; 2012 Feb; 72(3):301-6. PubMed ID: 21713964
[TBL] [Abstract][Full Text] [Related]
38. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome.
Zhu Y; Ren S; Jing T; Cai X; Liu Y; Wang F; Zhang W; Shi X; Chen R; Shen J; Lu J; Xu C; Wang H; Wang H; Wang Y; Liu B; Li Y; Fang Z; Guo F; Qiao M; Shen D; Lu X; Gao X; Hou J; Sun Y
Urol Oncol; 2015 Sep; 33(9):384.e9-20. PubMed ID: 26008593
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Jiang Z; Woda BA
Adv Anat Pathol; 2004 Nov; 11(6):316-21. PubMed ID: 15505533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
